Danny Bar-Zohar, a surgeon and pharmaceutical industry executive, has joined Syncona Ltd as partner to help the investment group build its portfolio of life science companies. Dr Bar-Zohar joins from Novartis where he was most recently global head of clinical development and analytics, leading late-stage clinical programmes in neuroscience, immunology, oncology and ophthalmology. Prior to that, he worked at Teva Pharmaceutical Industries Ltd. Dr Bar-Zohar studied medicine at the Sackler Faculty of Medicine at Tel-Aviv University in Israel and practiced general surgery at the Tel-Aviv Sourasky Medical Center.
Syncona announced the appointment on 30 April 2020.
Copyright 2020 Evernow Publishing Ltd.